In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...

IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...

-- BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

Since it has a market capitalisation of US$939m, IGM Biosciences' US$176m in cash burn equates to about 19% of its market value. As a result, we'd venture that the company could raise more cash for ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London ...

Check the time stamp on this data. Updated AI-Generated Signals for Igm Biosciences Inc. (IGMS) available here: IGMS.

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. These ...

Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago. These figures are ...

Additionally, thymic IgM B cells reactive to adducts were more likely to recognize ... and filtered through a 40 μm cell strainer (BD Biosciences). Thymocyte cell suspensions were then cryopreserved ...